Cumberland Pharmaceuticals
CPIX
29 hedge funds and large institutions have $36.2M invested in Cumberland Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 4 closing their positions.
0.19% more ownership
Funds ownership: 34.48% → 34.67% (+0.19%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less funds holding
Funds holding: 31 → 29 (-2)
10% less capital invested
Capital invested by funds: $40.1M → $36.2M (-$3.84M)
10% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 10
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Ariel Investments
Chicago,
Illinois
|
+$715K |
| 2 |
Renaissance Technologies
New York
|
+$160K |
| 3 |
Prudential Financial
Newark,
New Jersey
|
+$142K |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$111K |
| 5 |
BA
Ballew Advisors
Jackson,
Mississippi
|
+$38.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JAM
JW Asset Management
Miami Beach,
Florida
|
-$585K |
| 2 |
BlackRock
New York
|
-$308K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$134K |
| 4 |
Invesco
Atlanta,
Georgia
|
-$77K |
| 5 |
JP Morgan Chase
New York
|
-$62K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
SEI Investments
Oaks,
Pennsylvania
| $22K | +$5.16K | +749 | +29% |
|
|
OC
27
Oakworth Capital
Birmingham,
Alabama
| $20K | – | – | – |
|
28
UBS Group
Zurich,
Switzerland
| $10K | -$5.38K | -781 | -35% |
|
|
TRCT
29
Tower Research Capital (TRC)
New York
| $3K | -$2K | -290 | -40% |
|
|
30
Invesco
Atlanta,
Georgia
| – | -$77K | -10,500 | Closed |
|
|
31
JP Morgan Chase
New York
| – | -$62K | -8,378 | Closed |
|
|
TDC
32
Thompson Davis & Co
Richmond,
Virginia
| – | -$9K | -1,250 | Closed |
|
|
MA
33
MUFG Americas
New York
| – | -$1K | -140 | Closed |
|
CPIX Hedge Fund Activity: Q1 2018 in Review
29 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Cumberland Pharmaceuticals (CPIX) for Q1 2018, worth a combined $36.2M — down 9.6% from $40.1M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of CPIX and 2 opened new positions — a net loss of 2 holders — while 10 trimmed existing stakes and 9 added.
The largest buyer was Ariel Investments, adding an estimated $715K. The largest seller was JW Asset Management, cutting an estimated $585K.
- 29 institutional investors held Cumberland Pharmaceuticals (CPIX) as of Q1 2018, down from 31 in Q4 2017.
- Funds reported $36.2M of Cumberland Pharmaceuticals stock for Q1 2018, down 9.6% quarter-over-quarter.
- 2 funds opened new Cumberland Pharmaceuticals positions in Q1 2018 and 4 closed out, a net change of -2 holders.
- The largest Cumberland Pharmaceuticals buyer in Q1 2018 was Ariel Investments, an estimated $715K added.
- The largest Cumberland Pharmaceuticals seller in Q1 2018 was JW Asset Management, an estimated $585K sold.
Based on aggregated 13F filings for Q1 2018.